Abtis Co.
Latest round
- Series B
Last raised
- Feb 2021
Total raised
- $18M
Investors
- 10
About Abtis Co.
Based in South Korea, and founded in 2016, AbTis operates as a biotech company specializing in the development of Antibody-Drug Conjugate(ADC). In 2016, it established a corporate research institute. In 2019, it selected Korea-Canada International joint technology development project., Ltd., Ltd., Ltd. will hold 51% majority stake of the company. The company's pipelines are designed to enhance the safety and efficacy of the current antibody-drug conjugates, which apply to the native antibodies, commercial antibodies, or novel antibodies under development.
Who invested in Abtis Co.
10 investors across 2 rounds
See all investors in Abtis Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Abtis Co.
Who invested in Abtis Co.?
Abtis Co. has 10 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Abtis Co. raised?
Abtis Co. has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Abtis Co. last raise money?
Abtis Co.'s most recent round on record is a Series B, in Feb 2021.
What does Abtis Co. do?
Based in South Korea, and founded in 2016, AbTis operates as a biotech company specializing in the development of Antibody-Drug Conjugate(ADC).
Where is Abtis Co. headquartered?
Abtis Co. is headquartered in Suwon, South Korea.
Which VCs invest in companies like Abtis Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Abtis Co.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Abtis Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.